{"analyses":[{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"96.6","ciUpperLimit":"0.91","estimateComment":"Stratified Cox proportional hazard model","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A over Treatment B","nonInferiorityType":"SUPERIORITY","pValue":"0.0020","pValueComment":"Boundary for statistical significance was a p-value \\< 0.0345","paramType":"Hazard Ratio (HR)","paramValue":"0.74","statisticalComment":"This is 2 sided p-value from log-rank test stratified by histology and sex as entered in the IRT","statisticalMethod":"Stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.82","upperLimit":"21.45","value":"18.07"},{"groupId":"OG001","lowerLimit":"12.45","upperLimit":"16.23","value":"14.09"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W","id":"OG000","title":"Treatment A"},{"description":"Pemetrexed 500 mg/m\\^2 + Cisplatin 75 mg/m\\^2 or Carboplatin 5 AUC up to 6 cycles","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death (Up to 40 Months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}